Psoriatic Arthritis — When Psoriasis Attacks the Joints

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis occurring in people with psoriasis. It is not osteoarthritis (wear and tear) — it is immune-driven inflammation attacking joints, tendons, and entheses (the sites where tendons and ligaments attach to bone). The same immune dysregulation (IL-17/IL-23/TNF pathways) driving skin psoriasis also drives joint inflammation.

Key facts: Approximately 30% of psoriasis patients develop PsA at some point. Skin psoriasis precedes joint symptoms in 70% of cases — usually by 7-12 years. In 15% of cases, joint symptoms appear before skin psoriasis. In 15%, they appear simultaneously. Nail psoriasis is strongly associated with PsA — patients with nail involvement have significantly higher PsA risk. PsA can cause irreversible joint damage — early diagnosis and treatment is significantly more effective than late.

The joint damage problem: unlike osteoarthritis which progresses slowly, PsA can cause erosive joint destruction relatively quickly in some patients. X-rays showing joint space narrowing and erosions — changes that cannot be reversed. This is the strongest argument for not waiting and watching.

PsA has five recognised clinical patterns, often overlapping:

The pattern matters for prognosis and treatment decisions. Rheumatology assessment identifies the pattern.

The window between first joint symptoms and established joint damage is the critical treatment opportunity.

Dactylitis: the single most specific sign of PsA. An entire finger or toe swells uniformly — "sausage finger/toe." Not just one joint — the whole digit. This happens because PsA inflames tendons running through the digit. If a psoriasis patient develops a sausage finger — go to rheumatology immediately.

Enthesitis: pain and tenderness at entheses — the attachment points of tendons and ligaments to bone. Classic sites: heel pain (Achilles enthesis), pain under the heel (plantar fascia). Heel pain worst in the morning and improves with movement, in a psoriasis patient — consider PsA.

Morning stiffness in joints lasting more than 30 minutes — distinct from mechanical pain. Inflammatory stiffness improves with movement.

DIP joint swelling: swelling and pain in the last joint before the fingernail, especially with nail changes on the same finger.

Back pain in a young person with psoriasis, worst after prolonged rest and improves with movement — consider psoriatic spondylitis.

The practical rule: psoriasis patient + any joint symptom lasting more than 6 weeks + morning stiffness = rheumatology evaluation. Do not wait.

PsA diagnosis uses the CASPAR criteria — a scoring system combining clinical, radiological, and laboratory features. A score of 3 or more is classified as PsA.

CASPAR criteria: Evidence of psoriasis — 2 points for current psoriasis. Nail psoriasis (pitting, onycholysis) — 1 point. Negative rheumatoid factor — 1 point. Dactylitis — 1 point. Radiological evidence of juxta-articular bone formation — 1 point.

Blood tests: RF (Rheumatoid Factor) — usually negative in PsA, important distinction from RA. Anti-CCP — usually negative. ESR and CRP — elevated in active inflammation. HLA-B27 — positive in ~25% of PsA spondylitis cases. Uric acid — to rule out gout (can coexist).

Imaging: X-rays for erosions and new bone formation (periostitis) — characteristic of PsA. MRI — better for early enthesitis and sacroiliitis before X-ray changes appear.

Rheumatologist assessment: the definitive step — clinical examination of all joints, entheses, skin and nails, combined with tests and imaging.

Treatment goal: prevent joint damage, control inflammation, maintain function — alongside managing skin psoriasis.

NSAIDs: first-line for mild PsA. Anti-inflammatory drugs (naproxen, diclofenac, celecoxib) reduce pain and stiffness. Do not prevent joint damage. Appropriate for mild, non-erosive disease.

DMARDs for moderate-to-severe PsA: Methotrexate — first-line DMARD. Evidence reasonable for peripheral joint disease, limited for axial (spine) involvement. Weekly dose, blood monitoring required. Sulfasalazine — alternative for peripheral joint PsA. Leflunomide — alternative DMARD option.

Biologics: most effective for moderate-to-severe PsA. TNF inhibitors (adalimumab, etanercept), IL-17 inhibitors (secukinumab, ixekizumab — also very effective for skin), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib). Biosimilars reducing costs in India.

What does NOT work: hydroxychloroquine (antimalarial) — can specifically worsen PsA, should be avoided. Used in RA but contraindicated in PsA.

Physiotherapy: essential for maintaining joint mobility and function, especially for spine involvement. Cannot replace anti-inflammatory treatment but prevents deconditioning.

Psoriatic arthritis represents one of the most compelling indications for constitutional homoeopathic treatment — because the skin and joint components are part of the same systemic constitutional disease, and constitutional treatment addresses both simultaneously.

The systemic nature is the key point: PsA is a systemic immune disease expressing at skin, nails, and joints. Constitutional homoeopathic treatment is inherently systemic — it works through the constitutional picture of the whole person. A constitutional prescription addresses the overall immune dysregulation expressing simultaneously at skin and joints — not each site separately.

In practice: patients with PsA in homoeopathic practice often report that both skin and joint symptoms respond together over committed treatment. This is consistent with constitutional treatment addressing the shared underlying mechanism.

Early mild PsA — the strongest indication: a psoriasis patient who has developed early dactylitis or enthesitis with no radiological damage yet — constitutional treatment is a reasonable primary approach during this window, alongside appropriate monitoring. The goal: addressing the immune pattern before erosive damage occurs.

Moderate-to-severe PsA: when significant joint inflammation is present and radiological damage is a real risk, conventional DMARDs or biologics are the first priority. Constitutional treatment can run alongside, aiming to reduce overall disease activity. Both can work together.

The nail-skin-joint connection: nail psoriasis, skin psoriasis, and psoriatic arthritis share the same constitutional depth. A constitutional prescription addressing all three components through the individual's unique totality — that is the homoeopathic approach.

Dr. Shadab Khan — Akola, Maharashtra — WhatsApp 8983458889 — psoriatic arthritis including early cases and as complement to conventional treatment, online India-wide.